celecoxib has been researched along with methotrexate in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.71) | 18.2507 |
| 2000's | 7 (20.00) | 29.6817 |
| 2010's | 20 (57.14) | 24.3611 |
| 2020's | 6 (17.14) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, HJ; Liu, B; Yang, HR; Yao, QQ; Zhi, Y | 1 |
| Kramer, N; Kushner, LJ; Rosenstein, ED | 1 |
| Geis, GS; Harper, KM; Hubbard, RC; Hunt, TL; Karim, A; Tolbert, DS | 1 |
| Wasko, MC; Wildy, KS | 1 |
| Toussirot, E; Wendling, D | 1 |
| Agarwal, N; Gupta, AK; Jain, SK; Yadava, RK | 1 |
| Olmarker, K | 1 |
| Kandefer-Szerszeń, M; Majdan, M; Parada-Turska, J; Rzeski, W; Turski, WA | 1 |
| El Bary, NA; El Mageed, HA; Ghany, AA; Hashem, T; Metwally, H | 1 |
| Endou, H; Fujimura, A; Kanai, Y; Maeda, A; Miyamoto, E; Saito, K; Tsuruoka, S; Ushijima, K | 1 |
| Honjo, H; Iwamoto, K; Uwai, Y | 1 |
| Blann, AD; Han, C; Harris, AL; Khan, OA; Kirichek, O; Middleton, MR; Patil, M; Payne, MJ; Protheroe, AS; Talbot, DC; Taylor, M | 1 |
| Abed, S; Alla, CA; André, N; Gentet, JC; Orbach, D; Padovani, L; Pasquier, E; Verschuur, A | 1 |
| Banavali, SD; D'cruz, AK; Noronha, V; Patil, V; Prabhash, K | 1 |
| Joshi, A; Krishna, V; Noronha, V; Patil, V; Prabhash, K | 1 |
| Lee, SK; Lee, SW; Park, JS; Park, MC; Park, YB | 1 |
| Arya, S; Banavali, S; Bhattacharjee, A; Bhosale, B; D'Cruz, A; Dhumal, S; Joshi, A; Juvekar, S; Muddu, VK; Noronha, V; Patil, VM; Prabhash, K | 1 |
| Chen, Y; Cui, L; Cui, Y; Gao, X; Liu, Y; Su, Y | 1 |
| Bordy, R; Demougeot, C; Prati, C; Totoson, P; Verhoeven, F; Wendling, D | 1 |
| Abraham, G; Banavali, S; Bhattacharjee, A; Chandrasekharan, A; Das, S; Dhumal, S; DSouza, H; Gota, V; Joshi, A; Kashyap, L; Kumar, S; Mahajan, A; Mahimkar, M; Menon, N; Mukadam, S; Nawale, K; Noronha, V; Pandey, M; Patil, VM; Prabhash, K; Sable, N; Simha, V; Solanki, B; Srinivas, S; Talreja, V | 1 |
| Gourd, E | 1 |
| Imaduddin, M; Kar, M; Muduly, DK; Sultania, M; Vigneshwaran, B | 1 |
| Agarwal, JP; Banavali, SD; Goud, S; Janu, A; Joshi, A; Kannan, S; Kumar, R; Mahajan, A; Menon, NS; More, S; Mummudi, N; Nakti, D; Noronha, V; Patil, VM; Pawar, A; Prabhash, K; Shah, S; Tibdewal, A; Yadav, A | 1 |
| Chen, SL; Lin, CS; Xu, Q; Zhang, LY; Zheng, HJ | 1 |
| Damerla, RR; Kamal, MV; Kumar, NAN; Pai, A; Palod, A; Rao, M; Sharan, K; Shetty, PS; Usman, N | 1 |
| Adhya, AK; Imaduddin, M; Kar, M; Majumdar, SKD; Muduly, DK; Parida, DK; Sultania, M | 1 |
5 review(s) available for celecoxib and methotrexate
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Current concepts regarding pharmacologic treatment of rheumatoid and osteoarthritis.
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Digestive System; Etanercept; Glucocorticoids; Humans; Hydroxychloroquine; Immunoglobulin G; Infliximab; Isoxazoles; Lactones; Leflunomide; Methotrexate; Osteoarthritis; Pyrazoles; Receptors, Tumor Necrosis Factor; Sulfasalazine; Sulfonamides; Sulfones | 2001 |
Recent progress in ankylosing spondylitis treatment.
Topics: Celecoxib; Controlled Clinical Trials as Topic; Diphosphonates; Drug Therapy; Humans; Methotrexate; Pamidronate; Pyrazoles; Spondylitis, Ankylosing; Sulfonamides; Tumor Necrosis Factor-alpha | 2003 |
A Mechanistic Review of Methotrexate and Celecoxib as a Potential Metronomic Chemotherapy for Oral Squamous Cell Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Head and Neck Neoplasms; Humans; Methotrexate; Mouth Neoplasms; Squamous Cell Carcinoma of Head and Neck | 2023 |
7 trial(s) available for celecoxib and methotrexate
| Article | Year |
|---|---|
Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Cross-Over Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Humans; Isoenzymes; Kidney; Male; Membrane Proteins; Methotrexate; Middle Aged; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Single-Blind Method; Sulfonamides; Urine | 1999 |
A phase II study of high-dose celecoxib and metronomic 'low-dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclophosphamide; Disease-Free Survival; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Prognosis; Pyrazoles; Salvage Therapy; Sulfonamides; Treatment Outcome | 2010 |
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-1; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cyclophosphamide; Female; Humans; Male; Matrix Metalloproteinase 9; Methotrexate; Middle Aged; Neoplasms; Pyrazoles; Sulfonamides | 2011 |
Pilot study of a pediatric metronomic 4-drug regimen.
Topics: Administration, Metronomic; Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Child; Child, Preschool; Cyclophosphamide; Female; Humans; Male; Maximum Tolerated Dose; Methotrexate; Neoplasms; Pilot Projects; Pyrazoles; Sulfonamides; Treatment Outcome; Vinblastine; Young Adult | 2011 |
A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Cisplatin; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Prospective Studies; Pyrazoles; Risk Factors; Sulfonamides; Treatment Outcome | 2015 |
Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Male; Methotrexate; Middle Aged; Mouth Neoplasms; Organoplatinum Compounds; Progression-Free Survival; Squamous Cell Carcinoma of Head and Neck | 2019 |
Oral metronomic chemotherapy after definitive chemoradiation in esophageal squamous cell carcinoma: a randomized clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Celecoxib; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Methotrexate | 2022 |
23 other study(ies) available for celecoxib and methotrexate
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Evaluation of pyrrolidine-based analog of jaspine B as potential SphK1 inhibitors against rheumatoid arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Enzyme Inhibitors; Freund's Adjuvant; Molecular Structure; Phosphotransferases (Alcohol Group Acceptor); Pyrrolidines; Rats; Sphingosine; Structure-Activity Relationship | 2021 |
Rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Aurothioglucose; Blood Loss, Surgical; Celecoxib; Dental Care for Chronically Ill; Humans; Methotrexate; Pyrazoles; Sjogren's Syndrome; Sulfonamides | 1999 |
Quadriparesis in a young female suffering from rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Cervical Vertebrae; Chloroquine; Cyclooxygenase Inhibitors; Female; Humans; Magnetic Resonance Imaging; Methotrexate; Pyrazoles; Quadriplegia; Radiography; Sulfonamides; Treatment Failure | 2003 |
Neovascularization and neoinnervation of subcutaneously placed nucleus pulposus and the inhibitory effects of certain drugs.
Topics: Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Celecoxib; Cyclooxygenase Inhibitors; Cytokines; Dermatologic Agents; Doxycycline; Enzyme Inhibitors; Infliximab; Intervertebral Disc; Intra-Abdominal Fat; Methotrexate; Neovascularization, Physiologic; Nerve Regeneration; Prostaglandins; Pyrazoles; Subcutaneous Tissue; Sulfonamides; Swine; Transplantation, Autologous; Wound Healing | 2005 |
Effect of glutamate receptor antagonists and antirheumatic drugs on proliferation of synoviocytes in vitro.
Topics: Animals; Antirheumatic Agents; Benzodiazepines; Benzodiazepinones; Celecoxib; Cell Line; Cell Proliferation; Cell Survival; Diclofenac; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Inhibitory Concentration 50; Methotrexate; Naproxen; Pyrazoles; Quinoxalines; Sulfasalazine; Sulfonamides; Synovial Membrane | 2006 |
Drug interaction between celecoxib and methotrexate in organic anion transporter 3-transfected renal cells and in rats in vivo.
Topics: Animals; Celecoxib; Cell Line; Drug Interactions; Humans; Kidney Tubules, Proximal; Male; Methotrexate; Organic Anion Transporters, Sodium-Independent; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Transfection | 2010 |
Inhibitory effect of selective cyclooxygenase-2 inhibitor lumiracoxib on human organic anion transporters hOAT1 and hOAT3.
Topics: Animals; Binding, Competitive; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Estrone; Etoricoxib; Humans; Inhibitory Concentration 50; Isoxazoles; Kinetics; Lactones; Methotrexate; Oocytes; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; p-Aminohippuric Acid; Pyrazoles; Pyridines; RNA, Complementary; Sulfonamides; Sulfones; Xenopus laevis | 2010 |
Metronomic chemotherapy in advanced oral cancers.
Topics: Administration, Metronomic; Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Mouth Neoplasms; Neoplasm Staging; Palliative Care; Pyrazoles; Sulfonamides | 2012 |
Oral metronomic chemotherapy in recurrent, metastatic and locally advanced head and neck cancers.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Head and Neck Neoplasms; Humans; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pyrazoles; Sulfonamides | 2013 |
Concurrent use of methotrexate and celecoxib increases risk of silent liver fibrosis in rheumatoid arthritis patients with subclinical reduced kidney function.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Cross-Sectional Studies; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Incidence; Kidney; Liver Cirrhosis; Male; Methotrexate; Middle Aged; Multivariate Analysis; Pilot Projects; Pyrazoles; Risk Factors; Sulfonamides; Time Factors; Treatment Outcome | 2014 |
Effects of dexamethasone, celecoxib, and methotrexate on the histology and metabolism of bone tissue in healthy Sprague Dawley rats.
Topics: Animals; Antirheumatic Agents; Biomarkers; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Celecoxib; Dexamethasone; Female; Femur; Lumbar Vertebrae; Methotrexate; Osteoporosis; Rats; Rats, Sprague-Dawley; X-Ray Microtomography | 2015 |
Structural efficacy of NSAIDs, COX-2 inhibitor and glucocorticoid compared with TNFα blocker: a study in adjuvant-induced arthritis rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Experimental; Celecoxib; Cyclooxygenase 2 Inhibitors; Etanercept; Glucocorticoids; Hindlimb; Methotrexate; Naproxen; Prednisone; Rats; Treatment Outcome; Tumor Necrosis Factor-alpha | 2019 |
Metronomic chemotherapy option for advanced oral cancer.
Topics: Administration, Metronomic; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Erlotinib Hydrochloride; Humans; Methotrexate; Mouth Neoplasms; Progression-Free Survival | 2019 |
Metronomic therapy using Methotrexate and Celecoxib: A Boon for Oral Cancer patients during COVID-19 Pandemic.
Topics: Carcinoma; Celecoxib; Cisplatin; COVID-19; Humans; Methotrexate; Mouth Neoplasms; Neoplasm Recurrence, Local; Pandemics; SARS-CoV-2 | 2021 |
Case report: Joint deformity associated with systemic lupus erythematosus.
Topics: Adult; Antibodies, Antinuclear; Antigens, Nuclear; Arthritis, Rheumatoid; C-Reactive Protein; Celecoxib; Complement C3; DNA; Female; Humans; Lupus Erythematosus, Systemic; Methotrexate; Prednisone | 2022 |
Metronomic Therapy in Palliation of Oral Cancer Patients-A Home Based Approach at the End of Life.
Topics: Celecoxib; Death; Humans; Methotrexate; Middle Aged; Mouth Neoplasms; Palliative Care; Prospective Studies | 2022 |